专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060070139A1 Corn event DAS-59122-7 and methods for detection thereof 有权
公开(公告)号：US20060070139A1
公开(公告)日：2006-03-30
申请号：US11237222
申请日：2005-09-28
申请人： James Bing , Robert Cressman , Manju Gupta , Salim Hakimi , David Hondred , Todd Krone , Mary Hartnett Locke , Abigail Luckring , Sandra Meyer , Daniel Moellenbeck , Kenneth Narva , Paul Olson , Craig Sanders , Jimei Wang , Jian Zhang , Gan-Yuan Zhong
发明人： James Bing , Robert Cressman , Manju Gupta , Salim Hakimi , David Hondred , Todd Krone , Mary Hartnett Locke , Abigail Luckring , Sandra Meyer , Daniel Moellenbeck , Kenneth Narva , Paul Olson , Craig Sanders , Jimei Wang , Jian Zhang , Gan-Yuan Zhong
IPC分类号： A01H5/00 , C12Q1/68 , C07H21/04 , C12N15/82 , C12N5/04 , A01H1/00
CPC分类号： C12Q1/6876 , C07K14/415 , C12N15/8277 , C12N15/8286 , C12Q1/6895 , C12Q2600/13 , Y02A40/162
摘要： The invention provides DNA compositions that relate to transgenic insect resistant maize plants. Also provided are assays for detecting the presence of the maize DAS-59122-7 event based on the DNA sequence of the recombinant construct inserted into the maize genome and the DNA sequences flanking the insertion site. Kits and conditions useful in conducting the assays are provided.

2. 发明授权

US08198020B2 Compositions and methods for enhancing phagocytosis or phagocyte activity 有权
标题翻译：用于增强吞噬作用或吞噬细胞活性的组合物和方法
公开(公告)号：US08198020B2
公开(公告)日：2012-06-12
申请号：US10923940
申请日：2004-08-23
申请人： Cedric Francois , Pascal Deschatelets , Paul Olson , Alec Machiels
发明人： Cedric Francois , Pascal Deschatelets , Paul Olson , Alec Machiels
IPC分类号： C12Q1/70 , C12Q1/00 , G01N33/53 , G01N33/567 , G01N33/574
CPC分类号： B82Y5/00 , A61K47/544 , A61K47/62 , A61K47/6911 , A61K47/6913
摘要： The present invention provides a system for enhancing clearance or destruction of undesirable cells or noncellular molecular entities by tagging such cells or noncellular molecular entities with a marker that targets the cells or noncellular molecular entities for phagocytosis (phagocytic marker). The target cells can be, for example, endothelial cells, tumor cells, leukocytes, or virus-infected cells. In certain embodiments of the invention the tagging is accomplished by administering a composition comprising an antibody or ligand linked to the phagcytotic marker, wherein the antibody or ligand binds to a cell type specific marker present on or in the cell surface of a target cell. In preferred embodiments of the invention, the phagocytic marker comprises phosphatidylserine or a group derived from phosphatidylserine, thrombospondin-1, annexin I, or a derivative of any of these.
摘要翻译：本发明提供了一种用于通过用靶向细胞或非细胞分子实体进行吞噬作用（吞噬标记）的标记来标记这样的细胞或非细胞分子实体来增强不需要的细胞或非细胞分子实体的清除或破坏的系统。靶细胞可以是例如内皮细胞，肿瘤细胞，白细胞或病毒感染的细胞。在本发明的某些实施方案中，标记通过施用包含与噬菌体标记物连接的抗体或配体的组合物来实现，其中所述抗体或配体结合存在于靶细胞的细胞表面上或细胞表面的细胞类型特异性标志物。在本发明的优选实施方案中，吞噬标记物包含磷脂酰丝氨酸或衍生自磷脂酰丝氨酸，血小板反应素-1，膜联蛋白I或其任何衍生物的基团。

3. 发明申请

US20080075755A1 Viral Complement Control Proteins for Eye Disorders 失效
标题翻译：用于眼部疾病的病毒补体控制蛋白
公开(公告)号：US20080075755A1
公开(公告)日：2008-03-27
申请号：US11612751
申请日：2006-12-19
申请人： Pascal Deschatelets , Paul Olson , Cedric Francois
发明人： Pascal Deschatelets , Paul Olson , Cedric Francois
IPC分类号： A61K38/16 , A61K9/00 , A61P27/02
CPC分类号： A61K38/162 , A61K9/0051 , A61K38/17
摘要： The present invention provides compositions and methods for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof. Other compositions comprise a poxvirus complement control protein linked to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the methods comprise administering a poxvirus complement control protein or complement binding fragment or variant thereof to a subject.
摘要翻译：本发明提供用于治疗和/或预防年龄相关性黄斑变性和涉及黄斑变性或脉络膜新生血管形成，眼部炎症或其任何组合的其它病症的组合物和方法。某些组合物包含痘病毒补体对照蛋白或其补体结合片段或变体。其他组合物包含与结合存在于细胞或非细胞分子实体的表面或其表面上的组分连接的部分的痘病毒补体对照蛋白，例如存在于患有年龄相关性黄斑的风险的患者的眼睛中的组分变性或相关病症或脉络膜新生血管形成，眼部炎症或这些的任何组合。某些方法包括向受试者施用痘病毒补体对照蛋白或补体结合片段或其变体。

4. 发明申请

US20070061917A1 Methods and compositions for the expression of a polynucleotide of interest 审中-公开
标题翻译：用于表达感兴趣的多核苷酸的方法和组合物
公开(公告)号：US20070061917A1
公开(公告)日：2007-03-15
申请号：US11508045
申请日：2006-08-22
申请人： Billy McCutchen , Christine Hazel , Donglong Liu , Albert Lu , Wayne Mehre , Paul Olson , James Wong
发明人： Billy McCutchen , Christine Hazel , Donglong Liu , Albert Lu , Wayne Mehre , Paul Olson , James Wong
IPC分类号： A01H5/00 , C12N15/82 , C12N5/04 , C12N15/87
CPC分类号： C12N15/8274 , C12N9/1092 , C12N9/88 , C12N15/8205 , C12N15/8209 , C12N15/8216 , C12N15/8271 , C12N15/8275 , C12N15/8278 , C12N15/8286 , Y02A40/162
摘要： Methods and compositions for expressing a polynucleotide of interest are provided. Compositions comprise an enhancer domain set forth in SEQ ID NO: 1, 10, 15, or 16 and active variants and fragments thereof. Further provided are DNA constructs comprising at least one transcriptional enhancer sequence comprising the nucleotide sequence set forth in SEQ ID NO:1, 10, 15, or 16 or an active variant or fragment thereof, operably linked to a heterologous promoter. Such chimeric transcription regulatory regions can be operably linked any polynucleotide of interest. Further provided are cells, plants, plant parts, and germplasm comprising the DNA construct. Methods of using the chimeric transcriptional regulatory region are also provided. In specific embodiments, methods of expressing a polynucleotide of interest, including for example, sequences that confer tolerance to herbicides, and methods to select a cell having the DNA construct are provided.
摘要翻译：提供了表达感兴趣的多核苷酸的方法和组合物。组合物包含SEQ ID NO：1，10，15或16所示的增强子结构域及其活性变体和片段。还提供了包含至少一个转录增强子序列的DNA构建体，所述转录增强子序列包含可操作地连接到异源启动子的SEQ ID NO：1,0,15或16所示的核苷酸序列或其活性变体或片段。这样的嵌合转录调控区域可以可操作地连接任何感兴趣的多核苷酸。还提供了包含DNA构建体的细胞，植物，植物部分和种质。还提供了使用嵌合转录调节区的方法。在具体实施方案中，提供了表达目标多核苷酸的方法，包括例如赋予除草剂耐受性的序列，以及选择具有DNA构建体的细胞的方法。

5. 发明授权

US09182396B2 Lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders 有权
标题翻译：用于补体激活的侧流免疫测定和补体相关疾病的点护理评估的使用方法
公开(公告)号：US09182396B2
公开(公告)日：2015-11-10
申请号：US13287432
申请日：2011-11-02
申请人： Paul Olson , Don W. Moss
发明人： Paul Olson , Don W. Moss
IPC分类号： A61K39/395 , G01N33/00 , G01N33/53 , G01N33/566 , G01N33/564 , G01N33/558 , G01N33/86
CPC分类号： G01N33/68 , G01N33/558 , G01N33/564 , G01N33/86 , G01N2333/4716 , G01N2800/125 , G01N2800/26 , G01N2800/7095
摘要： A method for treating an individual at risk for a complement-associated disorder is provided, including: (a) obtaining a sample of a body fluid from the individual; (b) measuring a complement activation level in the sample via a point-of-care lateral flow immunoassay; (c) correlating the complement activation level in the sample to a risk of a complement-associated disorder by comparing the complement activation level in the sample to a reference level in a control, wherein a deviation in complement activation level in the sample compared to the reference level in the control indicates the individual is at risk for a complement-associated disorder; (d) selecting a treatment for the individual, based on the correlating of step (c); and (e) treating the individual with the treatment selected in accordance with step (d). Lateral flow immunoassays and a method of monitoring an individual suffering from a complement-associated disorder are also provided herein.
摘要翻译：提供了治疗患有补体相关疾病风险的个体的方法，包括：（a）从个体获得体液样品; （b）通过点护理侧流免疫测定法测量样品中的补体活化水平; （c）通过将样品中的补体激活水平与对照中的参考水平进行比较，将样品中的补体活化水平与补体相关疾病的风险相关联，其中样品中的补体活化水平的偏差与对照组的参考水平表明个体患有补体相关疾病的风险; （d）基于步骤（c）的相关性选择个体的治疗; 和（e）按照步骤（d）选择的治疗方法治疗个体。本文还提供侧流免疫测定和监测患有补体相关病症的个体的方法。

6. 发明授权

US08043609B2 Viral complement control proteins for eye disorders 失效
标题翻译：用于眼睛疾病的病毒补体对照蛋白
公开(公告)号：US08043609B2
公开(公告)日：2011-10-25
申请号：US11612751
申请日：2006-12-19
申请人： Pascal Deschatelets , Paul Olson , Cedric Francois
发明人： Pascal Deschatelets , Paul Olson , Cedric Francois
IPC分类号： A61K35/00 , C07K5/00
CPC分类号： A61K38/162 , A61K9/0051 , A61K38/17
摘要： The present invention provides compositions and methods for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof. Other compositions comprise a poxvirus complement control protein linked to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the methods comprise administering a poxvirus complement control protein or complement binding fragment or variant thereof to a subject.
摘要翻译：本发明提供用于治疗和/或预防年龄相关性黄斑变性和涉及黄斑变性或脉络膜新生血管形成，眼部炎症或其任何组合的其它病症的组合物和方法。某些组合物包含痘病毒补体对照蛋白或其补体结合片段或变体。其他组合物包含与结合存在于细胞或非细胞分子实体的表面或其表面上的组分连接的部分的痘病毒补体对照蛋白，例如存在于患有年龄相关性黄斑的风险的患者的眼睛中的组分变性或相关病症或脉络膜新生血管形成，眼部炎症或这些的任何组合。某些方法包括向受试者施用痘病毒补体对照蛋白或补体结合片段或其变体。

7. 发明申请

US20110092446A1 COMPOSITIONS AND METHODS FOR TREATMENT OF TRAUMA 审中-公开
标题翻译：组合物和治疗TRAUMA的方法
公开(公告)号：US20110092446A1
公开(公告)日：2011-04-21
申请号：US12669957
申请日：2008-07-21
申请人： Cedric Francois , Pascal Deschatelets , Paul Olson
发明人： Cedric Francois , Pascal Deschatelets , Paul Olson
IPC分类号： A61K38/12 , C12Q1/68 , C07K7/64
CPC分类号： A61K38/12 , C12Q1/6883 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156
摘要： The present invention features the use of a complement inhibitor, e.g., a compstatin analog for treating an individual who has suffered a severe injury. In some embodiments, the complement inhibitor may be administered within 24 hours following the injury and optionally also at later time points. The complement inhibitor may, for example, be administered prior to transporting the patient to a health care facility, during transport of the patient to a health care facility, or in the emergency department. Further provided are methods of selecting individuals for such therapy. Further provided are methods of identifying individuals at increased risk of poor outcome following trauma. In certain embodiments the methods comprise determining whether the genotype of the patient includes an allele of a polymorphism in or near a complement-related gene, wherein said allele is associated with risk of poor outcome following trauma.
摘要翻译：本发明的特征在于补体抑制剂例如化合物类似物用于治疗遭受严重损伤的个体的用途。在一些实施方案中，补体抑制剂可以在损伤后24小时内和任选地也在稍后的时间点施用。例如，补体抑制剂可以在将患者运送到保健设施之前，在将患者运送到保健设施或急诊部门期间进行给药。还提供了选择这种治疗的个体的方法。进一步提供的是识别创伤后不良结局风险增加的个体的方法。在某些实施方案中，所述方法包括确定患者的基因型是否包括在补体相关基因中或其附近的多态性的等位基因，其中所述等位基因与创伤后的结果不良的风险相关。

8. 发明授权

US09056076B2 Method of treating age-related macular degeneration comprising administering a compstatin analog 有权
标题翻译：治疗年龄相关性黄斑变性的方法，包括施用化合物抑制素类似物
公开(公告)号：US09056076B2
公开(公告)日：2015-06-16
申请号：US13409941
申请日：2012-03-01
申请人： Pascal Deschatelets , Paul Olson , Cedric Francois
发明人： Pascal Deschatelets , Paul Olson , Cedric Francois
IPC分类号： A61K38/12 , A61K38/10 , A61K9/00 , A61K31/00 , A61K38/08 , A61K38/17 , A61F9/00
CPC分类号： C07K7/08 , A61F9/0008 , A61K9/0019 , A61K9/0048 , A61K9/0051 , A61K31/00 , A61K31/7105 , A61K38/00 , A61K38/08 , A61K38/10 , A61K38/12 , A61K38/17 , A61K39/3955 , A61K49/0008 , A61K2039/505 , A61K2039/507 , C07K16/28 , C07K2319/01 , G01N33/6872 , G01N2333/4704 , G01N2500/04 , G01N2500/20
摘要： The present invention features the use of compstatin and complement inhibiting analogs thereof for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, choroidal neovascularization, and/or retinal neovascularization. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a second therapeutic agent. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a gel-forming material, e.g., soluble collagen, and methods of administering the compositions.
摘要翻译：本发明的特征在于使用化合物抑制剂和补体抑制类似物来治疗和/或预防年龄相关性黄斑变性和涉及黄斑变性，脉络膜新生血管形成和/或视网膜新生血管形成的其它病症。本发明还提供了包含抑制剂或其补体抑制类似物和第二治疗剂的组合物。本发明还提供了包含抑制抑制剂或其补体抑制类似物和凝胶形成材料例如可溶性胶原蛋白的组合物，以及施用组合物的方法。

9. 发明授权

US08580735B2 Local complement inhibition for treatment of complement-mediated disorders 有权
标题翻译：用于治疗补体介导的疾病的局部补体抑制
公开(公告)号：US08580735B2
公开(公告)日：2013-11-12
申请号：US12525799
申请日：2008-02-05
申请人： Cedric Francois , Pascal Deschatelets , Paul Olson
发明人： Cedric Francois , Pascal Deschatelets , Paul Olson
IPC分类号： A61K38/00 , A61K38/10
CPC分类号： A61K39/3955 , A61K38/12 , A61K38/17 , A61K45/06 , C07K7/64 , C07K14/435
摘要： The present invention features the local administration of complement inhibitors for treatment of complement-mediated disorders. In certain embodiments the invention features inhibiting activation of one or more locally produced complement proteins. The invention provides sustained release formulations and devices comprising a complement inhibitor and methods of use thereof.
摘要翻译：本发明的特征在于用于治疗补体介导的病症的补体抑制剂的局部施用。在某些实施方案中，本发明特征在于抑制一种或多种局部产生的补体蛋白的活化。本发明提供持续释放制剂和包含补体抑制剂的装置及其使用方法。

10. 发明申请

US20120315266A1 DETECTING COMPLEMENT ACTIVATION 有权
标题翻译：检测补充活动
公开(公告)号：US20120315266A1
公开(公告)日：2012-12-13
申请号：US13461709
申请日：2012-05-01
申请人： Paul Olson , Don W. Moss , Nicholas Staten
发明人： Paul Olson , Don W. Moss , Nicholas Staten
IPC分类号： G01N33/566 , A61P29/00 , A61P31/00 , A61P27/02 , A61P25/00 , A61P13/12 , A61K39/395 , A61P9/00
CPC分类号： G01N33/564 , G01N33/5306 , G01N2333/4716 , G01N2800/104 , G01N2800/125 , G01N2800/26 , G01N2800/52
摘要： Methods of detecting complement activation including steps of detecting in a sample from a subject a level of iC3b wherein the detecting involves specific interaction between the iC3b and a non-cross-reactive antibody thereto, comparing the detected level with a reference level, which reference level is within a range of about 10 ng/ml to about 5,000 ng/ml, wherein determination that the detected level is above the reference level indicates that the subject is suffering from or susceptible to undesirable and/or pathologic complement activation, and administering treatment to treat undesired complement activation if the detected level is above the reference level. Other methods of detecting complement activation with or without measuring iC3b are also provided.
摘要翻译：检测补体激活的方法，包括在受试者的样品中检测iC3b水平的步骤，其中检测涉及iC3b与非交叉反应性抗体之间的特异性相互作用，将检测到的水平与参考水平进行比较，哪个参考水平在约10ng / ml至约5,000ng / ml的范围内，其中确定检测到的水平高于参考水平表明受试者患有或不期望的和/或病理性补体激活易感，并且对如果检测到的水平高于参考水平，则处理不需要的补体激活。还提供了检测具有或不具有测量iC3b的补体激活的其它方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式